Audited Standalone & Consolidated Financial Results of the company for the Quarter and Financial year Ended 31st March, 2026.

Going-concern doubtEmphasis of matterRevenue growth above 20%Profit growth above 25%Results restatedResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.3%Reaction day

₹1.17

prior close

₹1.22

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%+4.2% vs market

Trading & Distributors peers, median of 131sector+0.0%+4.3% vs sector

On the reaction day the stock moved 4.2 pts more than Nifty Microcap 250 and 4.3 pts more than its Trading & Distributors peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.3+0.1+4.2+0.0+4.3

Next day

+9.4+1.7+7.7+0.4+9.1

+10.3+2.4+7.9+1.1+9.1

+6.8+2.4+4.5+0.5+6.3

+1.7+1.7-0.0+0.0+1.7

+0.9+0.6+0.3-0.0+0.9

-0.9+1.9-2.8-0.6-0.2

15d

-3.4+4.9-8.3-0.7-2.8

-4.3+8.9-13.2-0.1-4.2

-8.5+7.5-16.1-4.8-3.8

-12.8+13.6-26.4-5.1-7.7

UpDownMarket · Nifty Microcap 250Sector · Trading & Distributors peers, median of 131Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Genpharmasec Limited reported audited standalone revenue of ₹13,134.94 Lakhs for FY2026, a massive jump from ₹3,296.07 Lakhs in FY2025 (approx. 298% YoY growth), driven partly by the acquisition of Derren Healthcare Private Limited (70% stake, effective July 2025) which became a subsidiary. Standalone PAT grew to ₹544.96 Lakhs from ₹280.04 Lakhs (approx. 95% YoY). The company reclassified equity shares worth Rs. 89.32 Lakhs from Inventories to Financial Investments (FVOCI) as a retrospective change in accounting policy. Statutory auditor Bilimoria Mehta & Co. issued an unmodified opinion for both standalone and consolidated results. On consolidation, one subsidiary (Derren) posted a net loss of ₹346.76 Lakhs and cash outflow of ₹108.27 Lakhs. Operating cash flow turned positive at ₹192.76 Lakhs vs negative ₹136.80 Lakhs in the prior year.

Likely market impact

Strong standalone financial performance with multi-fold revenue and PAT growth is positive. However, auditors have flagged going concern uncertainty for two subsidiaries (Derren Healthcare and Clinigenome India), which have eroded net worth and current liabilities exceeding current assets, creating contingent risk for the Group.